Filing Details

Accession Number:
0001127602-24-005191
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-15 16:01:31
Reporting Period:
2024-02-13
Accepted Time:
2024-02-15 16:01:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1363076 M Robert Davis Merck &Amp; Co., Inc.
126 East Lincoln Avenue
Rahway NJ 07065
Chairman, Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-13 41,509 $75.36 389,836 No 4 M Direct
Common Stock Acquisiton 2024-02-13 108,491 $73.73 498,327 No 4 M Direct
Common Stock Disposition 2024-02-13 124,676 $125.74 373,651 No 4 S Direct
Common Stock Disposition 2024-02-13 25,324 $126.37 348,327 No 4 S Direct
Common Stock Acquisiton 2024-02-14 85,021 $73.73 433,348 No 4 M Direct
Common Stock Disposition 2024-02-14 85,021 $125.40 348,327 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-02-13 41,509 $0.00 41,509 $75.36
Common Stock Stock Option (Right to Buy) Disposition 2024-02-13 108,491 $0.00 108,491 $73.73
Common Stock Stock Option (Right to Buy) Disposition 2024-02-14 85,021 $0.00 85,021 $73.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
83,020 2021-05-01 2030-04-30 No 4 M Direct
181,781 2022-05-04 2031-05-03 No 4 M Direct
96,760 2022-05-04 2031-05-03 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.2700 to $126.2600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.2650 to $126.525, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.0900 to $125.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
  5. The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
  6. The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.